Advancing Diabetes Care Education Center
The patient population for diabetes is expanding rapidly, with almost 10% of the American population impacted by the disease. As this burden increases, so does the amount of other factors that physician needs to be aware of when treating patients with diabetes. Treating and preventing comorbidities, such as cardiovascular issues, now plays a major role in diabetes treatment.
This education center aims to updated primary care physicians, diabetes experts, and cardiologists treating patients with diabetes on the most recent advances in patient-centered diabetes care.
.jpg)
Body Weight, Blood Pressure Reductions Persist With Canagliflozin Use
November 14, 2018.jpg "FDA Approves Canagliflozin to Reduce CV risk in Type 2 Diabetes")
FDA Approves Canagliflozin to Reduce CV risk in Type 2 Diabetes
December 12, 2018For the first time, an oral diabetes therapy has been approved by the FDA to reduce the risk of major adverse cardiovascular events. Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of canagliflozin...
.jpg "Liraglutide Could Cut Cardiovascular Events in Older Patients")
Liraglutide Could Cut Cardiovascular Events in Older Patients
December 10, 2018.jpg "SGLT2 Inhibitors Shown to Lower Heart Failure Risk in T2D")
SGLT2 Inhibitors Shown to Lower Heart Failure Risk in T2D
December 4, 2018.jpg "Proteinuria Dipstick Test Can Help Determine T2D Cardiovascular Risk")
Proteinuria Dipstick Test Can Help Determine T2D Cardiovascular Risk
November 14, 2018A simple and inexpensive test can help detect the risk of cardiovascular events in patients with diabetes...
.jpg "SGLT2i Shows Better Cardiometabolic Effects in T2D Patients than DPP4i")
SGLT2i Shows Better Cardiometabolic Effects in T2D Patients than DPP4i
November 14, 2018
